Who makes Glycopyrronium MDI 28.8 micrograms?

Glycopyrronium MDI 28.8 micrograms is developed by Pearl Therapeutics, Inc..

What development phase is Glycopyrronium MDI 28.8 micrograms in?

Glycopyrronium MDI 28.8 micrograms is in Phase 2.

Last reviewed 2026-04-19 · How we verify

Glycopyrronium MDI 28.8 micrograms

Pearl Therapeutics, Inc. · Phase 2 active Small molecule

At a glance

Generic name	Glycopyrronium MDI 28.8 micrograms
Sponsor	Pearl Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Glycopyrronium MDI 28.8 micrograms CI brief — competitive landscape report
Glycopyrronium MDI 28.8 micrograms updates RSS · CI watch RSS
Pearl Therapeutics, Inc. portfolio CI